BRIEF-RepliCel forms strategic plan for 2017-2019 focused on maturing assets

* RepliCel Life Sciences Inc - RepliCel continues to make significant progress on its nearest-term commercial asset, dermal injector (RCI-02)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.